Specifically, neoadjuvant therapy in patients with breast cancer resulted in increased risk for metastasis.49 Thus, it is worth studying whether the addition of anti-IL-6 to the neoadjuvant treatment protocol can potentially reduce the risk for metastasis. Here, IL6 is linked to breast cancer.